Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
OBJECTIVE
The purpose of this study was to develop an immunocytokine for immunotherapy of human ovarian cancer.


METHODS
The single-chain Fv of a monoclonal antibody, COC183B2, specific for an ovarian carcinoma-associated antigen (OC183B2), was genetically fused with the coding sequence of interleukin 2 (IL-2). The fusion protein, also called immunocytokine, IL-2-183B2scFv, was expressed in CHO cells and examined for its specificity and biological function.


RESULTS
The immunocytokine, IL-2-183B2scFv, retained the functions of both the antibody and IL-2. It was able to target IL-2 to tumor cells that overexpress OC183B2, and stimulate the proliferation of an IL-2-dependent cell line, CTLL-2.


CONCLUSIONS
The IL-2-183B2scFv maintains the functions of both IL-2 and antibody. It can be potentially used for immunotherapy of ovarian cancer by delivering a high concentration of IL-2 to OC183B2-expressing ovarian cancer cells.
Zhang
Xinyan
X
Cancer Research Program, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham 27707, USA, and Gynecological Oncology Center, Peking University People's Hospital, Beijing, P. R. China. xzhang@nccu.edu
Feng
Jie
J
Ye
Xue
X
Yao
Yu
Y
Zhou
Ping
P
Chen
Xiaoxin
X
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D051379:Mice; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D011956:Receptors, Cell Surface / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007376:Interleukin-2; D011956:Receptors, Cell Surface; D011993:Recombinant Fusion Proteins